CND Life Sciences to Present at Biotech Showcase Investor Conference
Poised for Growth After Successful Launching First Skin-Based Test for Parkinson s
News provided by
Share this article
PHOENIX, Jan. 8, 2021 /PRNewswire/ CND Life Sciences (
cndlifesciences.com), an innovative medical technology company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, will participate in the 2021 virtual Biotech Showcase taking place during the 39th Annual J.P. Morgan Healthcare Conference (January 11-14, 2021). The company is capitalizing on a wave of forward momentum fueled by the first full-year of commercialization and adoption of its
for Parkinson s disease and other neurological disorders.
(2)
The global Phase 4 RESPOND study will evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical response to Zolgensma
Clinical and real-world experience have reported that some patients previously treated with Zolgensma have also been treated with SPINRAZA
1,2,3,4
Biogen remains committed to exploring the potential of SPINRAZA to optimize outcomes for patients with SMA
CAMBRIDGE, Mass., Jan. 08, 2021(Nasdaq: BIIB) today announced that the first patient has been treated in the global clinical study, RESPOND. The Phase 4 study will examine the clinical benefit and assess the safety of SPINRAZA (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet clinical needs following treatment with gene therapy Zolgensma
Research Finds Blood Vessel Damage, Inflammation in the Brains of COVID-19 Patients pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.
Biogen Inc.
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
The global Phase 4 RESPOND study will evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical response to Zolgensma
Clinical and real-world experience have reported that some patients previously treated with Zolgensma have also been treated with SPINRAZA
1,2,3,4
Biogen remains committed to exploring the potential of SPINRAZA to optimize outcomes for patients with SMA
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) Biogen Inc. (Nasdaq: BIIB) today announced that the first patient has been treated in the global clinical study, RESPOND. The Phase 4 study will examine the clinical benefit and assess the safet